Protalix biotherapeutics, inc. (PLX) 2025Q3 financial report shows revenue of 17.85M USD, with a YoY growth rate of -0.60%. Although revenue has slightly decreased compared to the same period last year, reflecting changes in industry demand, the company’s operations remain relatively stable. To fully assess Protalix biotherapeutics, inc. (PLX)’s potential risks and future development, investors should continue to monitor subsequent financial reports and strategic adjustments, and use diversified data analysis, including Growin AI Value Analysis, for a prudent and comprehensive evaluation.